|By Marketwired .||
|May 1, 2014 05:00 AM EDT||
SAN DIEGO, CA -- (Marketwired) -- 05/01/14 -- Ivera Medical Corporation, headquartered in San Diego, CA, announced that the United States District Court for the Southern District of California has rendered summary judgment against some Ivera patents, in motions filed by Excelsior Medical, Hospira, and Catheter Connections. The case involves U.S. Patent Nos. 7,780,794 ("the '794 patent"), 7,985,302 ("the '302 patent"), and 8,206,514 ("the '514 patent").
"We are disappointed in the Court's decision and are evaluating our options, including an appeal of this decision, and note that these patents continue through an inter partes review process within the US Patent and Trademark office," said Bob Rogers, CEO of Ivera Medical. "Our strategy regarding intellectual property has always been to build a robust portfolio, so that an adverse ruling in one case does not impact the broader strategy. Indeed, Ivera continues to be very pleased with our progress in a Florida court patent infringement case, and the impending issuance of what will be the seminal patent in this space, for which we have an exclusive license. Further it is important to note that Ivera has freedom to operate with our Curos® Port Protectors."
Curos products employ passive disinfection to disinfect intravenous devices eliminating the technique variation found in manual procedures. With two disinfecting port protector options -- Curos Strips and individual Curos -- nurses can conveniently comply with valve disinfection protocols by simply peeling the foil seal from the distinctive green cap and twisting Curos onto the top of any luer-activated IV access port or needleless valve. Inside Curos, a 70% isopropyl alcohol (IPA) saturated sponge-like foam bathes the surface of the venous access device to provide consistent and reliable disinfection of the port surface in three minutes. Once in place, Curos maintains a clean port for up to seven days, if not removed. Extending passive disinfection and protection to male-luer connectors, Curos Tips improve disinfection compliance with IV tubing connectors and needleless syringes by immersing the exterior of the male luer in alcohol. Curos Tips come in a convenient strip dispenser that places five disinfecting Tips in easy reach of clinicians at the point of care. The cap's highly visible bright green color allows auditors to monitor caregiver disinfection practice compliance at a glance.
About Ivera Medical
Ivera Medical Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing and sale of products that help healthcare providers reduce facility-acquired patient infections. Curos, manufactured in Carlsbad, CA, is the first disinfecting cap to be marketed in the U.S. and has received FDA's 510(k) market clearance. For more information about Curos and Ivera Medical, visit the website at www.curos.com
Vice President, Business Development
Ivera Medical Corp.
Aug. 3, 2015 07:00 AM EDT Reads: 187
Aug. 3, 2015 06:45 AM EDT Reads: 254
Aug. 2, 2015 10:00 PM EDT Reads: 678
Aug. 2, 2015 06:00 PM EDT Reads: 1,128
Aug. 2, 2015 05:45 PM EDT Reads: 511
Aug. 2, 2015 04:00 PM EDT Reads: 422
Aug. 2, 2015 03:00 PM EDT Reads: 546
Aug. 2, 2015 12:00 PM EDT Reads: 346
Aug. 2, 2015 11:45 AM EDT Reads: 480
Aug. 2, 2015 11:15 AM EDT Reads: 354
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Aug. 2, 2015 11:00 AM EDT Reads: 175
Aug. 2, 2015 09:00 AM EDT Reads: 1,698
Aug. 2, 2015 08:15 AM EDT Reads: 184
Aug. 1, 2015 10:00 AM EDT Reads: 338
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
Aug. 1, 2015 09:45 AM EDT Reads: 207